Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02829372
Title Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers (GBR 1302-101)
Acronym GBR 1302-101
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Glenmark Pharmaceuticals S.A.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | DEU


No variant requirements are available.